Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Palazestrant |
Trade Name | |
Synonyms | OP1250|OP 1250|OP-1250 |
Drug Descriptions |
Palazestrant is a Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), which blocks the activity of the AF1 and AF2 domains of the estrogen receptor, potentially resulting in decreased cell proliferation and inhibition of tumor growth (PMID: 38102750). |
DrugClasses | Hormone - Anti-estrogens 29 |
CAS Registry Number | 2092925-89-6 |
NCIT ID | C176877 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abemaciclib + Palazestrant | Abemaciclib Palazestrant | 0 | 0 |
Alpelisib + Palazestrant | Alpelisib Palazestrant | 0 | 1 |
Palazestrant | Palazestrant | 0 | 2 |
Palazestrant + Palbociclib | Palazestrant Palbociclib | 0 | 1 |
Palazestrant + Ribociclib | Palazestrant Ribociclib | 0 | 1 |
Palazestrant + Trastuzumab | Palazestrant Trastuzumab | 0 | 0 |
Palazestrant + Tucatinib | Palazestrant Tucatinib | 0 | 0 |